Nilotinib is a targeted drug of several generations

Nilotinib (Nilotinib) is a second-generation oral targeted drug therapy that is a tyrosine kinase inhibitor. It is not considered a traditional chemotherapy ("chemo") treatment, but it is used to kill cancer. Targeted drug therapies find and attack specific types of cancer cells and may cause less damage to healthy cells. Targeted drug treatments can still cause serious side effects.

The U.S. Food and Drug Administration (FDA) approved nilotinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+CML) in adults and children at least 1 year old. Chronic myelogenous leukemia is a cancer of the blood and bone marrow. Nilotinib is 30 times more potent than imatinib, has high affinity and selectivity for BCR/ABL, and is also active against a variety of mutant clones in addition to the T315I mutation. Phase II trials of nilotinib have shown high activity in patients with imatinib-resistant or intolerant CML, while first-line treatment of chronic-phase disease has shown rapid and stable cytogenetic responses and increasing molecular responses.

The original drug Nilotinib is marketed in China under the name Nilotinib and is covered by medical insurance, but reimbursement is limited to patients who meet the indications. SpecificationsThe price of 150mg*120 tablets per box may be around 9,000 yuan. The Indian version of Nilotinib is available overseas. The price of Nilotinib's original drug, 150mg*28 capsules per box, may be around RMB 1,000 (the price may fluctuate due to exchange rates). The ingredients of the original drug sold domestically and abroad are basically the same. Currently, there is no generic version of Nilotinib produced and launched. For more drug information and specific prices, please consult Yaode Medical Consultants.